Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from May 25, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 23, 2026 — +17.9% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$1,020.00 – $1,060.00Entry zone — fair-value band

$1,065.00Published — price the day we called it

$1,214.10Target — the price the thesis aimed for

$1,292.65Peak — highest point inside the window, not a realized return

$1,255.40Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 32 days.

At window close

+17.9%

realized, from the publication price to the last close inside the window

Peak gain

+21.4%

peak, from the publication price — not a realized return

S&P 500, same window

+3%

SPY over the identical days, dividend-adjusted

Window close

$1,255.40

last close inside the window, ended August 23, 2026

Peak price

$1,292.65

peak on August 19, 2026 — not a realized return

Days to target

The thesis — published May 25, 2026

Predicted growth

+14%

over the measurement window

Target price

$1,214.10

the price the thesis aimed for

Entry zone

$1,020.00 – $1,060.00

the fair-value band we waited for

Price at publication

$1,065.00

published May 25, 2026

Confidence

80%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly stands out as a large pharmaceutical company with fast growth driven by obesity, diabetes and cardiometabolic drugs. Recent positive updates on retatrutide and VERVE-102 give near-term reasons for interest. The stock ran up quickly and could be volatile soon, but strong earnings, a deep drug pipeline and defensive healthcare exposure support a constructive short-term setup if price calms.

Primary drivers

Positive retatrutide results strengthen the weight-loss drug program
VERVE-102 news adds optional benefits for cardiometabolic treatment
Leading diabetes and obesity products create steady demand
Healthcare sector exposure provides defensive qualities

How it played out

LLY: target reached in 32 days

Lyra published the LLY thesis on May 25 at $1,065, expecting 14% growth. The thesis pointed to retatrutide results, VERVE-102 news, demand for diabetes and obesity products, and defensive healthcare exposure. It also noted that the stock had risen quickly and could be volatile.

The price reached the $1,214.10 target in 32 days. It later peaked at $1,292.65 on August 19, a 21.4% gain. LLY ended the window at $1,255.40, still above the target. The published thesis played out and exceeded its stated price objective.

What happened during the window

On August 3, Lilly announced that the FDA had granted Breakthrough Therapy designation to olomorasib for certain previously treated advanced pancreatic cancers. On August 5, Lilly reported second-quarter results and raised its full-year guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals